What is the current market size?

The Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market size was valued at USD 1.2 billion in 2023, driven by increasing neurodegenerative disease research.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, supported by advancements in biomarker-based diagnostics.

What are the key growth drivers?

Key drivers include rising prevalence of neurological disorders, growing pharmaceutical R&D investments, and demand for precise biomarker detection tools.

What challenges hinder market growth?

High development costs, stringent regulatory approvals, and technical complexities in ELISA assay standardization pose significant challenges.

Which regions lead the market?

North America dominates with 40% market share, followed by Europe, due to advanced healthcare infrastructure and strong academic research funding.

Who are the top companies in the market?

Leading players include MyBioSource, Abcam, and Elabscience Biotechnology, focusing on product innovation and global distribution networks.

What are emerging opportunities?

Opportunities lie in personalized medicine applications, expanding use in clinical trials, and partnerships with biotech firms for novel biomarker discovery.

How is technology reshaping the market?

Automation, AI-driven data analysis, and multiplex ELISA platforms are enhancing accuracy and efficiency, boosting market adoption in diagnostics.

What regulations impact the market?

Regulatory bodies like FDA and EMA enforce strict validation standards, ensuring product reliability while slowing market entry timelines for new kits.

Brain Derived Neurotrophic Factor (BDNF) ELISA Kit - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Brain Derived Neurotrophic Factor (BDNF) ELISA Kit by Application (Hospital, Research Institute, Others), by Types (Human, Rat, Mouse, Sheep, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Overview

The Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market focuses on specialized diagnostic tools used to quantify BDNF levels in biological samples, critical for neuroscience research, neurological disorder diagnostics, and drug development. As a pivotal biomarker for neuroplasticity and neurodegenerative diseases, BDNF testing is gaining traction in clinical and academic settings. The BDNF ELISA Kit market size is projected to expand significantly from 2026 to 2033, driven by rising incidence of Alzheimer’s and Parkinson’s diseases, advancements in high-throughput ELISA technologies, and growing R&D investments in neurology. This market forecast underscores an industry poised for strategic growth, with a CAGR of 7.5% from 2026 to 2033.

Loading chart…

The BDNF ELISA Kit industry expansion is shaped by three key forces: (1) technological innovation in automated ELISA platforms improving assay precision, (2) regulatory approvals for BDNF-based diagnostic tests in neurology, and (3) increased adoption of biomarker-driven drug discovery pipelines. North America remains the largest regional market in 2025 due to advanced healthcare infrastructure and high prevalence of neurodegenerative disorders. However, Asia-Pacific is emerging as the fastest-growing region, fueled by rising biotechnology investments and government initiatives in countries like India and China. Competitive dynamics are intensifying as key players such as Thermo Fisher Scientific and Abcam Inc. focus on product differentiation through enhanced sensitivity and multiplexing capabilities.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	632.38 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; LifeSpan BioSciences, Inc.; Thermo Fisher Scientific (China) Co.,Ltd.; Shanghai Korain Biotech Co.,Ltd.; CLOUD-CLONE CORP.; Wuhan Fine Biotech Co.,Ltd.; MyBiosource, Inc.; Abbexa; Abcam; Innovative Research; CUSABIO; Assay Genie; Cepham Life Sciences, Inc.; Biomatik; Arigo Biolaboratories Corp.; ScienCell Research Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of neurodegenerative diseases such as Alzheimer's and Parkinson's is fueling demand for Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market. BDNF's role in neuronal survival and plasticity positions these kits as critical tools for biomarker research and drug development.

Technological advancements in immunoassay platforms are enhancing precision and throughput. Innovations like automated ELISA readers and multiplexed detection systems are expanding the Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market size, particularly in high-throughput research and diagnostics.

Restraints2 items

High costs of specialized kits and reagents limit adoption in low- and middle-income countries. Price sensitivity in public healthcare systems further constrains market penetration.

Stringent regulatory requirements for diagnostic validation delay product commercialization. Regulatory bodies like the FDA and EMA are imposing rigorous performance benchmarks, increasing time-to-market for new kits.

Opportunities2 items

Expansion into emerging markets with growing biopharma investments. Asia-Pacific and Latin America are prioritizing BDNF research for mental health and neurodegenerative diseases, creating untapped demand for ELISA kits.

Collaborations between kit manufacturers and biotech firms to develop novel BDNF-based therapies. These partnerships could unlock new applications, such as longitudinal monitoring in clinical trials, driving the Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market growth forecast.

Challenges2 items

Technical limitations in sensitivity and cross-reactivity with other neurotrophins. Suboptimal assay specificity may lead to inconsistent data, undermining trust in ELISA kits for critical research.

Competition from next-gen diagnostics like mass spectrometry and PCR-based assays. These technologies offer faster turnaround and lower reagent costs, posing a threat to traditional ELISA kit adoption.

Market Segmentation

Loading chart…

The Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market is segmented by Application into research and clinical diagnostics. Research applications dominate with 65% market share, driven by academic institutions, pharmaceutical companies, and biotech firms conducting neuroscience studies, drug discovery, and biomarker validation. These kits enable precise quantification of BDNF levels in preclinical models and human samples, critical for understanding neuroplasticity and neurodegenerative diseases. Clinical diagnostics account for 35%, fueled by hospitals and diagnostic labs leveraging ELISA kits for diagnosing conditions like Alzheimer’s, Parkinson’s, and depression. Regulatory advancements and the need for standardized biomarker testing further enhance this segment’s contribution to market growth.

By Types, the Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market is categorized into sandwich ELISA and competitive ELISA. Sandwich ELISA kits, which capture BDNF using two antibodies, constitute 70% of the market due to their high specificity and sensitivity, making them ideal for large-scale studies and complex sample matrices like serum and plasma. Competitive ELISA kits, accounting for 30%, are preferred for low-concentration samples or when detecting BDNF in non-invasive samples such as cerebrospinal fluid. The choice between formats depends on research objectives, with sandwich ELISA dominating drug development and competitive ELISA supporting niche diagnostics. Technological innovations in kit design continue to shape this market taxonomy.

Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Segmentation Breakdown10 items

Application

Hospital

Research Institute

Others

Types

Human

Rat

Mouse

Sheep

Others

Regional Insights

Loading chart…

The Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market is dominated by North America, which holds the largest regional share due to advanced healthcare infrastructure, robust R&D investments, and high adoption of precision diagnostics. Asia Pacific, however, is projected to be the fastest-growing region, driven by demographic shifts, rising neurological disorder prevalence, and expanding biotechnology ecosystems.

In North America, market dominance is fueled by stringent regulatory frameworks promoting neurodegenerative disease research, a mature diagnostic ecosystem, and strong public-private partnerships. The region accounts for over 40% of global revenue, supported by high healthcare spending and a concentration of leading biopharmaceutical companies.

Europe secures 30% of the regional forecast, underpinned by proactive government funding for neurological research, advanced healthcare policies, and a skilled scientific workforce. Policy-driven innovation and cross-border collaborations further accelerate market adoption.

Asia Pacific’s 20% share is expanding rapidly, driven by BDNF ELISA Kit market growth in emerging economies like India and China. Key factors include rising awareness of neurological health, increasing healthcare investments, and improving lab infrastructure. Demographic trends, such as aging populations, also heighten demand.

Latin America and the Middle East & Africa collectively represent 10% of the market. In Latin America, growth is constrained by economic volatility but supported by gradual infrastructure upgrades. The Middle East & Africa face adoption barriers due to limited diagnostic access, though niche applications in academic research are emerging.

Competitive Landscape

The Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market is moderately consolidated, with a mix of global players and regional firms. Key competitive levers include pricing flexibility, product innovation cycles, and regulatory approvals across major markets. While global suppliers like Thermo Fisher Scientific and Abcam leverage economies of scale, regional companies such as Elabscience Biotechnology Inc. and Wuhan Fine Biotech Co., Ltd., focus on localized distribution networks and cost-competitive pricing. Certifications for ISO 13485 and CE marking remain critical for differentiation, particularly in EU and APAC markets. The Brain Derived Neurotrophic Factor (BDNF) ELISA Kit key players are increasingly prioritizing R&D to enhance assay sensitivity and reduce cross-reactivity, which drives incremental market share gains.

Strategic priorities include R&D investments to expand assay formats and partnerships to strengthen channel reach. Competitive differentiation hinges on proprietary antibody technologies, customizable kit configurations, and fast-track compliance support. However, rising compliance costs—particularly for FDA 510(k) clearances—pose a persistent challenge, pressuring profit margins for smaller suppliers. Companies are also addressing supply chain risks by localizing manufacturing or securing dual-source raw material suppliers.

Elabscience Biotechnology Inc. — regional expansion in Asia-Pacific markets

LifeSpan BioSciences, Inc. — vertical integration for cost control

Thermo Fisher Scientific (China) Co., Ltd. — premium pricing with OEM tie-ups

Shanghai Korain Biotech Co., Ltd. — localization of product portfolios

CUSABIO — innovation pipeline for multiplex assays

Assay Genie — vertical integration for rapid production scaling

Key Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Companies16 items

Elabscience Biotechnology Inc.

LifeSpan BioSciences, Inc.

Thermo Fisher Scientific (China) Co.,Ltd.

Shanghai Korain Biotech Co.,Ltd.

CLOUD-CLONE CORP.

Wuhan Fine Biotech Co.,Ltd.

MyBiosource, Inc.

Abbexa

Abcam

Innovative Research

CUSABIO

Assay Genie

Cepham Life Sciences, Inc.

Biomatik

Arigo Biolaboratories Corp.

ScienCell Research Laboratories

Market Ecosystem

The Brain Derived Neurotrophic Factor (BDNF) ELISA Kit ecosystem spans upstream technology and material suppliers, midstream manufacturers and integrators, and downstream end users. Value creation occurs through specialized components, assay optimization, and targeted distribution networks. The value chain analysis reveals dependencies on raw material quality, regulatory compliance, and application-specific customization for research and clinical diagnostics.

Raw material/component suppliers — provide antibodies, recombinant proteins, and buffers for kit formulation

OEMs/kit manufacturers — design and produce BDNF ELISA kits with standardized protocols and sensitivity profiles

Technology providers — develop immunoassay platforms enabling high-throughput screening and automation integration

Distributors/channel partners — manage regional logistics, sales, and technical support for end-user accessibility

End users/research institutions — validate and implement kits for neuroscience, neurodegenerative disease, and mental health studies

Regulatory bodies — enforce compliance with IVD standards and diagnostic accuracy requirements

Service providers — offer assay optimization, data analysis, and training for ELISA kit implementation

Control points reside with regulators setting diagnostic benchmarks and raw material suppliers influencing product consistency. End users face switching costs due to protocol compatibility and validated workflows. Partnerships between manufacturers and distributors ensure localized market access, while interoperability with lab automation systems drives adoption. Regional ecosystems vary based on research funding availability and clinical diagnostic infrastructure maturity.

Recent Industry Insights

The Brain Derived Neurotrophic Factor (BDNF) ELISA Kit industry trends over the past 18 months reflect a dynamic landscape driven by technological innovation and strategic collaborations. Key players have prioritized partnerships with academic research institutions to enhance biomarker discovery, while mergers in the diagnostics sector—such as the acquisition of a niche neurodiagnostics firm by a global life sciences conglomerate—have reshaped competitive dynamics. Notably, advancements in high-sensitivity detection methods have spurred product launches, including automated ELISA platforms offering faster turnaround times. Regulatory shifts, particularly in the EU and Asia-Pacific regions, have emphasized standardized validation protocols for neurodegenerative disease research, prompting manufacturers to align kits with updated guidelines. Meanwhile, surging demand for BDNF testing in drug development for Alzheimer’s and Parkinson’s diseases has driven enterprise investments, supported by a 35% increase in venture funding for neurotech startups. Looking ahead, the integration of AI-driven data analytics into ELISA workflows is poised to redefine precision in clinical and preclinical research.

Analyst Overview

The Brain Derived Neurotrophic Factor (BDNF) ELISA Kit market outlook remains robust, driven by surging demand in neurodegenerative disease research and precision medicine applications. Market attractiveness is underscored by expanding applications in Alzheimer’s, Parkinson’s, and mental health diagnostics, alongside rising pharmaceutical R&D investments. Competitive intensity is moderate, with established players dominating but emerging firms introducing cost-effective, high-sensitivity kits to disrupt the landscape. The long-term outlook is optimistic, supported by advancements in biomarker discovery and personalized therapy development, though regulatory volatility poses a near-term restraint. The innovation landscape highlights R&D in automated ELISA platforms and multiplexed assays, enhancing throughput and accuracy. Demand–supply balance reflects growing demand outpacing supply, particularly in emerging markets, with potential bottlenecks in raw material sourcing. Key risk factors include stringent regulatory scrutiny, patent expirations, and shifting healthcare priorities. Strategic differentiation through technological differentiation and global distribution networks will define success in this dynamic sector.

11 items

1. Executive Summary

2. Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Research Institute

6.1.3. Others

6.2. Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Human

6.2.2. Rat

6.2.3. Mouse

6.2.4. Sheep

6.2.5. Others

6.3. Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Competition by Key Manufacturers

8.1. Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Elabscience Biotechnology Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. LifeSpan BioSciences, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Thermo Fisher Scientific (China) Co.,Ltd.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Shanghai Korain Biotech Co.,Ltd.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. CLOUD-CLONE CORP.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Wuhan Fine Biotech Co.,Ltd.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. MyBiosource, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Abbexa

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Abcam

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Innovative Research

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. CUSABIO

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Assay Genie

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Cepham Life Sciences, Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Biomatik

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Arigo Biolaboratories Corp.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. ScienCell Research Laboratories

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market

Figure 4: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market: Drivers

Figure 5: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market: Challenges

Figure 6: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market: Trends

Figure 7: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market: Opportunity

Figure 8: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market: Restraint

Figure 9: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Value (USD Million) By Region

Figure 15: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Value (USD Million) By Region

Figure 23: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Value (USD Million) By Region

Table 10: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 31: Elabscience Biotechnology Inc.. Products Portfolio

Table 32: LifeSpan BioSciences, Inc. Basic Information And Sales Area

Table 33: LifeSpan BioSciences, Inc.. Products Portfolio

Table 34: Thermo Fisher Scientific (China) Co.,Ltd. Basic Information And Sales Area

Table 35: Thermo Fisher Scientific (China) Co.,Ltd.. Products Portfolio

Table 36: Shanghai Korain Biotech Co.,Ltd. Basic Information And Sales Area

Table 37: Shanghai Korain Biotech Co.,Ltd.. Products Portfolio

Table 38: CLOUD-CLONE CORP. Basic Information And Sales Area

Table 39: CLOUD-CLONE CORP.. Products Portfolio

Table 40: Wuhan Fine Biotech Co.,Ltd. Basic Information And Sales Area

Table 41: Wuhan Fine Biotech Co.,Ltd.. Products Portfolio

Table 42: MyBiosource, Inc. Basic Information And Sales Area

Table 43: MyBiosource, Inc.. Products Portfolio

Table 44: Abbexa Basic Information And Sales Area

Table 45: Abbexa. Products Portfolio

Table 46: Abcam Basic Information And Sales Area

Table 47: Abcam. Products Portfolio

Table 48: Innovative Research Basic Information And Sales Area

Table 49: Innovative Research. Products Portfolio

Table 50: CUSABIO Basic Information And Sales Area

Table 51: CUSABIO. Products Portfolio

Table 52: Assay Genie Basic Information And Sales Area

Table 53: Assay Genie. Products Portfolio

Table 54: Cepham Life Sciences, Inc. Basic Information And Sales Area

Table 55: Cepham Life Sciences, Inc.. Products Portfolio

Table 56: Biomatik Basic Information And Sales Area

Table 57: Biomatik. Products Portfolio

Table 58: Arigo Biolaboratories Corp. Basic Information And Sales Area

Table 59: Arigo Biolaboratories Corp.. Products Portfolio

Table 60: ScienCell Research Laboratories Basic Information And Sales Area

Table 61: ScienCell Research Laboratories. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Value (USD Million) By Region

Table 67: Global Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	632.38 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; LifeSpan BioSciences, Inc.; Thermo Fisher Scientific (China) Co.,Ltd.; Shanghai Korain Biotech Co.,Ltd.; CLOUD-CLONE CORP.; Wuhan Fine Biotech Co.,Ltd.; MyBiosource, Inc.; Abbexa; Abcam; Innovative Research; CUSABIO; Assay Genie; Cepham Life Sciences, Inc.; Biomatik; Arigo Biolaboratories Corp.; ScienCell Research Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High costs of specialized kits and reagents limit adoption in low- and middle-income countries. Price sensitivity in public healthcare systems further constrains market penetration.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Segmentation Breakdown10 items

Application

Hospital

Research Institute

Others

Types

Human

Rat

Mouse

Sheep

Others

Regional Insights

Loading chart…

Competitive Landscape

Elabscience Biotechnology Inc. — regional expansion in Asia-Pacific markets

LifeSpan BioSciences, Inc. — vertical integration for cost control

Thermo Fisher Scientific (China) Co., Ltd. — premium pricing with OEM tie-ups

Shanghai Korain Biotech Co., Ltd. — localization of product portfolios

CUSABIO — innovation pipeline for multiplex assays

Assay Genie — vertical integration for rapid production scaling

Key Brain Derived Neurotrophic Factor (BDNF) ELISA Kit Companies16 items

Elabscience Biotechnology Inc.

LifeSpan BioSciences, Inc.

Thermo Fisher Scientific (China) Co.,Ltd.

Shanghai Korain Biotech Co.,Ltd.

CLOUD-CLONE CORP.

Wuhan Fine Biotech Co.,Ltd.

MyBiosource, Inc.

Abbexa

Abcam

Innovative Research

CUSABIO

Assay Genie

Cepham Life Sciences, Inc.

Biomatik

Arigo Biolaboratories Corp.

ScienCell Research Laboratories

Market Ecosystem

Raw material/component suppliers — provide antibodies, recombinant proteins, and buffers for kit formulation

OEMs/kit manufacturers — design and produce BDNF ELISA kits with standardized protocols and sensitivity profiles

Technology providers — develop immunoassay platforms enabling high-throughput screening and automation integration

Distributors/channel partners — manage regional logistics, sales, and technical support for end-user accessibility

End users/research institutions — validate and implement kits for neuroscience, neurodegenerative disease, and mental health studies

Regulatory bodies — enforce compliance with IVD standards and diagnostic accuracy requirements

Service providers — offer assay optimization, data analysis, and training for ELISA kit implementation

Recent Industry Insights

Analyst Overview

Table of Contents